{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:31:13Z","timestamp":1783096273673,"version":"3.54.6"},"reference-count":54,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000901","name":"Juvenile Diabetes Research Foundation International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008522","name":"University of Illinois at Chicago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008522","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ajpath.2020.06.004","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T11:19:42Z","timestamp":1592911182000},"page":"1971-1981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["The Renin-Angiotensin-Aldosterone System (RAAS) Is One of the Effectors by Which Vascular Endothelial Growth Factor (VEGF)\/Anti-VEGF Controls the Endothelial Cell Barrier"],"prefix":"10.1016","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1535-6099","authenticated-orcid":false,"given":"Yueru","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0006-2693","authenticated-orcid":false,"given":"Komal","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrius","family":"Kazlauskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2020.06.004_bib1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.preteyeres.2015.08.001","article-title":"The progress in understanding and treatment of diabetic retinopathy","volume":"51","author":"Stitt","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajpath.2020.06.004_bib2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1900\/RDS.2013.10.133","article-title":"Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment","volume":"10","author":"Hamilton","year":"2013","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.ajpath.2020.06.004_bib3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","article-title":"Diabetic retinopathy","volume":"376","author":"Cheung","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2020.06.004_bib4","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajpath.2020.06.004_bib5","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group","volume":"317","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.ajpath.2020.06.004_bib6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0140-6736(97)06209-0","article-title":"Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus","volume":"351","author":"Chaturvedi","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2020.06.004_bib7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S2213-8587(14)70256-6","article-title":"Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis","volume":"3","author":"Wang","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ajpath.2020.06.004_bib8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1146\/annurev.pharmtox.010909.105610","article-title":"Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy","volume":"50","author":"Bader","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.ajpath.2020.06.004_bib9","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrc2945","article-title":"The renin-angiotensin system and cancer: old dog, new tricks","volume":"10","author":"George","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ajpath.2020.06.004_bib10","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s001250051539","article-title":"Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes","volume":"43","author":"Gilbert","year":"2000","journal-title":"Diabetologia"},{"key":"10.1016\/j.ajpath.2020.06.004_bib11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/jcbfm.2008.154","article-title":"Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy","volume":"29","author":"Kim","year":"2009","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.ajpath.2020.06.004_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/01.ATV.0000149377.90852.d8","article-title":"Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice","volume":"25","author":"Ebrahimian","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ajpath.2020.06.004_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/HYPERTENSIONAHA.108.117663","article-title":"Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability","volume":"53","author":"Phipps","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.ajpath.2020.06.004_bib14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajpath.2020.06.004_bib15","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","article-title":"Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE","volume":"120","author":"Brown","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajpath.2020.06.004_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/jamaophthalmol.2015.4110","article-title":"Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: extrapolation of data to clinical practice","volume":"134","author":"Heier","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajpath.2020.06.004_bib17","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2020.06.004_bib18","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/eci.12557","article-title":"Genetic variants in the renin-angiotensin system predict response to bevacizumab in cancer patients","volume":"45","author":"Moreno-Munoz","year":"2015","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ajpath.2020.06.004_bib19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0003-2697(69)90089-X","article-title":"An improved method for the addition of long-chain free fatty acid to protein solutions","volume":"32","author":"Spector","year":"1969","journal-title":"Anal Biochem"},{"key":"10.1016\/j.ajpath.2020.06.004_bib20","series-title":"Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM","author":"Li","year":"2013"},{"key":"10.1016\/j.ajpath.2020.06.004_bib21","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ajpath.2020.06.004_bib22","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1093\/nar\/gks042","article-title":"Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation","volume":"40","author":"McCarthy","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ajpath.2020.06.004_bib23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ajpath.2020.06.004_bib24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B Methodol"},{"key":"10.1016\/j.ajpath.2020.06.004_bib25","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1038\/srep06207","article-title":"Critical limitations of consensus clustering in class discovery","volume":"4","author":"Senbabaoglu","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpath.2020.06.004_bib26","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1073\/pnas.0611510104","article-title":"Vascular endothelial tyrosine phosphatase (VE-PTP)-null mice undergo vasculogenesis but die embryonically because of defects in angiogenesis","volume":"104","author":"Dominguez","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2020.06.004_bib27","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1161\/ATVBAHA.111.244004","article-title":"FGD5 mediates proangiogenic action of vascular endothelial growth factor in human vascular endothelial cells","volume":"32","author":"Kurogane","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ajpath.2020.06.004_bib28","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1101\/gad.1134603","article-title":"RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development","volume":"17","author":"Adini","year":"2003","journal-title":"Genes Dev"},{"key":"10.1016\/j.ajpath.2020.06.004_bib29","doi-asserted-by":"crossref","first-page":"L517","DOI":"10.1152\/ajplung.00069.2016","article-title":"Phospholipase C-epsilon signaling mediates endothelial cell inflammation and barrier disruption in acute lung injury","volume":"311","author":"Bijli","year":"2016","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.ajpath.2020.06.004_bib30","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1084\/jem.20182151","article-title":"Endothelial ERK1\/2 signaling maintains integrity of the quiescent endothelium","volume":"216","author":"Ricard","year":"2019","journal-title":"J Exp Med"},{"key":"10.1016\/j.ajpath.2020.06.004_bib31","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S1097-2765(00)80221-X","article-title":"Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability","volume":"4","author":"Eliceiri","year":"1999","journal-title":"Mol Cell"},{"key":"10.1016\/j.ajpath.2020.06.004_bib32","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1165\/rcmb.2015-0328OC","article-title":"Selective role of vinculin in contractile mechanisms of endothelial permeability","volume":"55","author":"Birukova","year":"2016","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.ajpath.2020.06.004_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.devcel.2010.12.001","article-title":"Robo4 maintains vessel integrity and inhibits angiogenesis by interacting with UNC5B","volume":"20","author":"Koch","year":"2011","journal-title":"Dev Cell"},{"key":"10.1016\/j.ajpath.2020.06.004_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.vph.2016.05.003","article-title":"Regulation of endothelial homeostasis, vascular development and angiogenesis by the transcription factor ERG","volume":"86","author":"Shah","year":"2016","journal-title":"Vasc Pharmacology"},{"key":"10.1016\/j.ajpath.2020.06.004_bib35","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1073\/pnas.87.1.404","article-title":"Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory","volume":"87","author":"Roy","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2020.06.004_bib36","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2337\/diabetes.51.7.2241","article-title":"Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes","volume":"51","author":"Romeo","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.ajpath.2020.06.004_bib37","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1084\/jem.20081188","article-title":"Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia","volume":"205","author":"El-Osta","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.ajpath.2020.06.004_bib38","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2337\/diabetes.47.6.945","article-title":"Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products","volume":"47","author":"Chakravarthy","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.ajpath.2020.06.004_bib39","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1167\/iovs.02-0648","article-title":"Diabetic retinopathy and serum lipoprotein subclasses in the DCCT\/EDIC cohort","volume":"45","author":"Lyons","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajpath.2020.06.004_bib40","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1055\/s-2003-41284","article-title":"Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia","volume":"111","author":"Julius","year":"2003","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.ajpath.2020.06.004_bib41","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1096\/fj.01-0707fje","article-title":"Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression","volume":"16","author":"Joussen","year":"2002","journal-title":"FASEB J"},{"key":"10.1016\/j.ajpath.2020.06.004_bib42","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0002-9394(14)74052-8","article-title":"Cytokines in the vitreous of patients with proliferative diabetic retinopathy","volume":"114","author":"Abu el Asrar","year":"1992","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajpath.2020.06.004_bib43","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/sj.eye.6702138","article-title":"Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy","volume":"20","author":"Demircan","year":"2006","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ajpath.2020.06.004_bib44","first-page":"S7","article-title":"Endothelial adherens junctions: implications in the control of vascular permeability and angiogenesis","volume":"100 Suppl","author":"Dejana","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2020.06.004_bib45","doi-asserted-by":"crossref","first-page":"14361","DOI":"10.1038\/ncomms14361","article-title":"The molecular basis of endothelial cell plasticity","volume":"8","author":"Dejana","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2020.06.004_bib46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/03009734.2015.1064501","article-title":"Vascular permeability--the essentials","volume":"120","author":"Claesson-Welsh","year":"2015","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.ajpath.2020.06.004_bib47","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1126\/science.aat3470","article-title":"A unifying concept in vascular health and disease","volume":"360","author":"Schwartz","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2020.06.004_bib48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrm2639","article-title":"Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system","volume":"10","author":"Augustin","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ajpath.2020.06.004_bib49","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1161\/ATVBAHA.107.158014","article-title":"VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation","volume":"28","author":"Vestweber","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ajpath.2020.06.004_bib50","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ajo.2011.03.033","article-title":"Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema","volume":"152","author":"Sohn","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajpath.2020.06.004_bib51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nm1534","article-title":"Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation","volume":"13","author":"Gao","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpath.2020.06.004_bib52","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.exer.2018.05.003","article-title":"Inhibition of Cx43 gap junction uncoupling prevents high glucose-induced apoptosis and reduces excess cell monolayer permeability in retinal vascular endothelial cells","volume":"173","author":"Kim","year":"2018","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ajpath.2020.06.004_bib53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.exer.2016.08.005","article-title":"Dexamethasone reverses the effects of high glucose on human retinal endothelial cell permeability and proliferation in\u00a0vitro","volume":"151","author":"Stewart","year":"2016","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ajpath.2020.06.004_bib54","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/(SICI)1096-9896(1998110)186:3<306::AID-PATH183>3.0.CO;2-B","article-title":"Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours","volume":"186","author":"Stitt","year":"1998","journal-title":"J Pathol"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944020302959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944020302959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T16:37:30Z","timestamp":1757695050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944020302959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0002944020302959"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2020.06.004","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Renin-Angiotensin-Aldosterone System (RAAS) Is One of the Effectors by Which Vascular Endothelial Growth Factor (VEGF)\/Anti-VEGF Controls the Endothelial Cell Barrier","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2020.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}